Ariana Pelosci

Articles

HER2-Low Classification Is Associated With Distinct Clinical Features in Advanced Gastric Cancer

January 19th 2023

Clinicopathological features of HER2-low advanced gastric cancer were distinct and distinguishable from those of HER2-positive or -negative disease, according to retrospective findings from a single-institution study that were presented at the 2022 Gastrointestinal Cancers Symposium.

Tisagenlecleucel Elicits Sustained Responses in Relapsed/Refractory Follicular Lymphoma

December 12th 2022

Tisagenlecleucel produced durable responses in patients with relapsed/refractory follicular lymphoma, including those with high-risk disease characteristics.

Rituximab/Lenalidomide Shows Sustained PFS Benefit in Indolent Non-Hodgkin Lymphoma

December 10th 2022

The combination of rituximab and lenalidomide maintained improved progression-free survival compared with rituximab alone in patients with relapsed/refractory indolent non-Hodgkin lymphoma, according to 5-year findings from the phase 3 AUGMENT trial.

Capivasertib Plus Fulvestrant Elicits PFS Benefit in HR+/HER2- Advanced Breast Cancer

December 8th 2022

The combination of capivasertib plus fulvestrant significantly improved progression-free survival vs fulvestrant alone in patients with hormone receptor–positive/HER2-negative advanced breast cancer, including those with AKT pathway–altered tumors.

Pembrolizumab/Olaparib Combo Fails to Improve rPFS, OS Vs Novel Hormonal Agents in mCRPC

September 12th 2022

The combination of pembrolizumab and olaparib did not significantly improve radiographic progression-free survival and overall survival compared with novel hormonal agents in patients with molecularly unselected, previously treated metastatic castration-resistant prostate cancer.

Preoperative Nivolumab Alone or With Relatlimab Allows for Surgical Feasibility in Resectable NSCLC

September 9th 2022

Preoperative nivolumab with or without relatlimab increased surgical feasibility in patients with resectable non–small cell lung cancer.

Sintilimab Elicits Similar Efficacy, Safety Vs Pembrolizumab in Advanced NSCLC

August 7th 2022

Sintilimab, both as a single agent and in combination with chemotherapy, generated comparable efficacy and safety vs pembrolizumab in patients with untreated metastatic non–small cell lung cancer.

Tucatinib Plus First-Line Maintenance Under Exploration in Metastatic HER2+ Breast Cancer

June 8th 2022

Tucatinib plus first-line standard-of-care maintenance therapy with trastuzumab and pertuzumab is being investigated for its ability to improve progression-free survival and maintain health-related quality of life in patients with HER2-positive metastatic breast cancer.

Pembrolizumab Produces Prolonged Survival in NSCLC With PD-L1 TPS ≥ 90%

June 7th 2022

Treatment with frontline pembrolizumab demonstrated meaningful improvements in long-term survival in patients with EGFR- or ALK- wild-type non–small cell lung cancer and a tumor proportion score of at least 90% vs those with a tumor proportion score between 50% and 89%, according to 3-year findings from a correlative analysis.

Rucaparib Maintenance Shows PFS Benefit in Ovarian Cancer, Independent of HRD Status

June 6th 2022

Rucaparib elicited a significant improvement in progression-free survival outcomes vs placebo as first-line maintenance therapy in patients with ovarian cancer who responded to first-line platinum-based chemotherapy across patient subgroups.

Ixazomib/Daratumumab Elicits Encouraging Response in Elderly Frail Patients With R/R Multiple Myeloma

June 5th 2022

Ixazomib plus daratumumab without dexamethasone showed a positive efficacy profile for elderly frail patients with relapsed/refractory multiple myeloma, according to results of the phase 2 IFM 2018-02 study.

Iomab-B Yields Beneficial Rates of HCT in Relapsed/Refractory AML

April 26th 2022

The use of 131-iodine generated high rates of allogeneic hematopoietic cell transplantation in patients with relapsed/refractory acute myeloid leukemia who did not achieve a complete response following standard therapy.

Single Infusion of Cilta-Cel Elicits Early Responses in Myeloma

April 25th 2022

Ciltacabtagene autoleucel generated deep responses and demonstrated manageable safety in patients with progressive multiple myeloma who were refractory to lenalidomide.

Adebrelimab Plus Chemotherapy Improves Survival Vs Chemotherapy Alone in ES-SCLC

April 13th 2022

The addition of adebrelimab to chemotherapy elicited improved overall survival compared with chemotherapy and placebo in patients with extensive-stage small cell lung cancer.

Elimusertib Elicits Responses in Solid Tumors With ATM Alterations and BRCA Mutations

April 11th 2022

The oral ataxia-telangiectasia and Rad3–related protein inhibitor elimusertib produced durable and prolonged responses in patients with advanced solid tumors who have ATM gene alterations and BRCA1/2 defects.

Maintenance Niraparib Given at Individualized Starting Dose Improves PFS in Ovarian Cancer

March 20th 2022

When maintenance niraparib was administered at an individualized starting dose, it resulted in a statistically significant and clinically meaningful improvement in progression-free survival vs placebo in patients with newly diagnosed ovarian cancer, irrespective of biomarker status.

Real-World Analysis Shows Survival Benefit With Second-Line PARP Maintenance Over Active Surveillance in Ovarian Cancer

March 18th 2022

Patients with recurrent ovarian cancer who received PARP inhibitor maintenance treatment in the second-line setting experienced a longer time to next treatment and overall survival compared with those who were just under active surveillance.

Continuous Enzalutamide After Progression Improves PFS in Patients with mCRPC

February 18th 2022

Continuous enzalutamide plus docetaxel and prednisone elicited progression-free survival improvement vs placebo with docetaxel and prednisone in patients with metastatic castration-resistant prostate cancer who had previously progressed on enzalutamide alone

Utilization of ctDNA Assays Could Determine Benefit of Adjuvant Chemotherapy in Resectable CRC

January 24th 2022

The use of ctDNA assays may help identify patients with colorectal cancer who could benefit from adjuvant chemotherapy.

Oral Fluoropyrimidine Improves Survival as Adjuvant Therapy in Biliary Tract Cancer

January 21st 2022

The oral fluoropyrimidine derivative S-1 led to improved survival when used as adjuvant therapy compared with surgery alone in patients with biliary tract cancers.